Mishaela R. Rubin, MD
Schedule an Appointment
Phone Appointments
Connect Patient Portal
For existing patients, login to make an appointment, view documentation or contact your care provider.
Credentials & Experience
Board Certifications
- Endocrinology
Clinical Expertise
- Bone Disease
- Hypothyroidism
- Metabolic Bone Disease
Specialties
Education & Training
- Columbia University College of Physicians and Surgeons
- Residency: NewYork-Presbyterian Hospital/Columbia University Medical Center
- Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center
Honors & Awards
- Phi Beta Kappa, Barnard College, 1991
- Endocrine Fellows Foundation Award
- Mentored Patient-Oriented Research Career Development Award (K23, NIH), 2004-2009
- Patient-Oriented Research Track Scholarship (K30, NIH), 2004-2006
- Young Investigator Award, American Society of Bone and Mineral Research, 2006
About Mishaela Rubin
Dr. Mishaela Rubin is an Assistant Professor of Clinical Medicine. She attended Barnard College (1991) and Columbia University College of Physicians and Surgeons (1995), completing her Internal Medicine residency (1998) and Endocrinology fellowship training (2002) at Columbia University. Dr. Rubin also completed a Master's degree in Biostatistics at Columbia University (2006).
She received an Endocrine Fellows Foundation Award (2001), a Mentored Patient-Oriented Research Career Development Award (K23, NIH 2004-2009), a Patient-Oriented Research Track Scholarship (K30, NIH, 2004-2006) and a Young Investigator Award from the American Society of Bone and Mineral Research (2006). Dr. Rubin also received an Irving Scholarship for Young Investigators at Columbia University (2008-2011) as well as a CTSA/CTO Pilot Award (2008).
Academic Titles
- Associate Professor of Medicine at CUMC
Committee/Societies/Council Memberships
- Member, the Endocrine Society
2001 - Present - Member, American Society for Bone and Mineral Research
2002 - Present
Hospital Affiliations
- NewYork-Presbyterian / Columbia University Irving Medical Center
Gender
- Female
Insurance Accepted
Aetna
- EPO
- HMO
- Medicare Managed Care
- NYP Employee Plan
- NY Signature
- POS
- PPO
- Signature Administrators
- Student Health
AgeWell
- Medicare Managed Care
- Special Needs Plan
Capital District Physician Health Plan
- Capital District Physician Health Plan
Cigna
- EPO
- Great West
- HMO
- POS
- PPO
Emblem/HIP
- ConnectiCare
- EPO
- Essential Plan
- HMO
- Medicaid Managed Care
- Medicare Managed Care
- POS
- PPO
- Select Care (Exchange)
- Vytra
Empire Blue Cross Blue Shield
- EPO
- Medicare Managed Care
- PPO
Local 1199
- Local 1199
MagnaCare
- MagnaCare
Multiplan
- Multiplan
MVP Health Care
- Child/Family Health Plus
- Essential Plan
- HMO
- Medicaid Managed Care
Oxford Health Plans
- Freedom
- Liberty
UnitedHealthcare
- Columbia University Employee Plan
- Compass (Exchange)
- HMO
- Medicaid (Community Plan)
- Medicare Managed Care
- POS
- PPO
*Please contact the provider’s office directly to verify that your particular insurance is accepted.
Contact & Locations
New York, New York 10032
Research
Dr. Rubin's work has focused on hypoparathyroidism, as well as characterization of circulating osteogenic precursor cells, and the skeletal effects of Type 2 Diabetes Mellitus. She is currently a co-Investigator for NIH and FDA-funded studies in hypoparathyroidism and is the PI for a project investigating diabetes and bone (RC4, NIH, 2010-2012).
Grants
SKELETAL FRAGILITY IN TYPE 1 DIABETES: GLYCEMIC CONTROL AND BONE STRENGTH (Federal Gov)
Sep 12 2019 - Aug 31 2024
SKELETAL MICROSTRUCTURE-RACIAL DIFFERENCES AND GENETIC CONTRIBUTORS (Federal Gov)
Aug 1 2018 - Jul 31 2023
THERAPY OF THE SKELETAL DISEASE OF TYPE 2 DIABETES WITH DENOSUMAB (P&S Industry Clinical Trial)
Mar 20 2018 - Mar 20 2023
PROTOCOLSHP634-101, ENTITLED, ?AN OPEN-LABEL, RANDOMIZED, CROSSOVER STUDY TO ASSESS THE PHARMACOKINETIC AND PHARMACODYNAMIC PROFILES OF ONCE-DAILY AND TWICE-DAILY DOSE REGIMENS OF RECOMBINANT HUMAN PARATHYROID HORMONE (RHPTH[1-84]) (P&S Industry Clinical Trial)
Mar 16 2017 - Mar 16 2022
APHASE 4, OPEN-LABEL, SINGLE-CENTER CLINICAL STUDY OF EXTENDED USE OF RHPTH(1-84) IN HYPOPARATHYROIDISM (P&S Industry Clinical Trial)
Sep 20 2016 - Sep 20 2021
13/22 DIABETES PREVENTION PROGRAM OUTCOMES STUDY (DPPOS) PHASE 3 - RESEARCH PROJECT (Federal Gov)
Aug 15 1994 - Jan 31 2021
SKELETAL DISEASE IN TYPE 2 DIABETES: A NOVEL THERAPEUTIC APPROACH FOR THE ELDERLY (Federal Gov)
Dec 15 2017 - Nov 30 2020
EPIDEMIOLOGY OF DIABETES INTERVENTIONS AND COMPLICATIONS (Federal Gov)
Sep 30 2016 - Jun 30 2020
PRIMARY HYPERPARATHYROIDISM (Federal Gov)
Apr 1 2014 - Mar 31 2020
SKELETAL DISEASE IN TYPE 2 DIABETES: A NOVEL THERAPEUTIC APPROACH FOR THE ELDERLY (Federal Gov)
Dec 15 2017 - Nov 30 2019
PRIMARY HYPERPARATHYROIDISM (Federal Gov)
Apr 1 2014 - Mar 31 2019
PRIMARY HYPERPARATHYROIDISM (Federal Gov)
Apr 1 2014 - Mar 31 2019
PRIMARY HYPERPARATHYROIDISM (Federal Gov)
Apr 1 2014 - Mar 31 2019
EPIDEMIOLOGY OF DIABETES INTERVENTIONS AND COMPLICATIONS (Federal Gov)
Sep 30 2016 - Jun 30 2017
OSTEOPOROSIS IN HIV INFECTED POSTMENOPAUSAL WOMEN (Federal Gov)
Jul 1 2010 - Jun 30 2016
BONE PROPERTIES IN HYPOPARATHYROIDISM: EFFECT OF PTH (Federal Gov)
Dec 1 2004 - Jun 30 2016
VITAMIN D DEFICIENCY IN PRIMARY HYPERPARATHYROIDISM (Federal Gov)
Jul 1 2010 - Apr 30 2016
TREATMENT OF HYPOPARATHYROIDISM WITH PARATHYROID HORMONE (Federal Gov)
Sep 30 2005 - Jul 31 2014
CHD INCIDENCE: DEPRESSION AND VITAMIN D DEFICIENCY RISK (Private)
Jan 1 2012 - Dec 31 2013
CHD INCIDENCE: DEPRESSION AND VITAMIN D DEFICIENCY RISK (Private)
Jan 1 2012 - Dec 31 2013
THE SKELETAL EFFECTS OF REDUCING INFLAMMATION IN TYPE 2 DIABETES MELLITUS (Federal Gov)
Sep 30 2010 - Sep 29 2013
For a complete list of publications, please visit PubMed.gov